CINECA IRIS Institutional Research Information System

PELLEGRINI, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.452
EU - Europa 2.002
AS - Asia 631
AF - Africa 118
SA - Sud America 16
OC - Oceania 1
Totale 6.220
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.398
IT - Italia 1.069
SE - Svezia 280
CN - Cina 220
SG - Singapore 184
BG - Bulgaria 160
DE - Germania 108
VN - Vietnam 89
GB - Regno Unito 78
AT - Austria 71
CI - Costa d'Avorio 67
RU - Federazione Russa 56
CA - Canada 46
FI - Finlandia 45
HK - Hong Kong 36
SN - Senegal 35
IN - India 32
PL - Polonia 32
FR - Francia 31
IR - Iran 21
UA - Ucraina 15
BR - Brasile 13
CZ - Repubblica Ceca 13
JP - Giappone 13
TR - Turchia 12
BE - Belgio 11
CH - Svizzera 9
KR - Corea 7
MX - Messico 7
NG - Nigeria 6
ES - Italia 5
PK - Pakistan 5
GH - Ghana 3
IE - Irlanda 3
LB - Libano 3
NL - Olanda 3
PT - Portogallo 3
RO - Romania 3
BJ - Benin 2
DK - Danimarca 2
HU - Ungheria 2
MO - Macao, regione amministrativa speciale della Cina 2
NO - Norvegia 2
PH - Filippine 2
UG - Uganda 2
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
CU - Cuba 1
DZ - Algeria 1
EC - Ecuador 1
ID - Indonesia 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 6.220
Salva come PNG Salva come JPEG
Città #
Fairfield 482
Woodbridge 329
Ashburn 296
Chandler 279
Houston 224
Seattle 202
Wilmington 169
Cambridge 167
Milan 166
Sofia 160
Serra 157
Ann Arbor 139
New York 131
Pisa 124
Boardman 112
Beijing 87
Princeton 79
Abidjan 67
Singapore 67
Florence 64
Lawrence 60
Vienna 54
Rome 50
Dong Ket 48
Medford 48
Bremen 47
Des Moines 36
Ottawa 36
Dakar 35
London 34
Hong Kong 32
Lappeenranta 30
Ogden 29
Dearborn 25
Nanjing 24
Redwood City 22
Chicago 20
Warsaw 19
Pistoia 18
Dallas 16
Frankfurt am Main 16
Livorno 15
Bologna 14
Marseille 14
Washington 14
San Diego 13
Kent 12
Naples 12
Brno 11
Phoenix 11
Brussels 10
Los Angeles 10
Padova 10
Izmir 9
Nanchang 9
Lancaster 8
Munich 8
Palermo 8
Aguascalientes 7
Lucca 7
Montecatini Terme 7
Turin 7
Ancona 6
Brescia 6
Changsha 6
Kunming 6
Lagos 6
Redmond 6
Columbus 5
Norwalk 5
Parma 5
Pune 5
Shenzhen 5
Tagliacozzo 5
Toronto 5
Apucarana 4
Atlanta 4
Ballabio 4
Boulder 4
Busto Arsizio 4
Guangzhou 4
Haikou 4
Hebei 4
Hefei 4
Jacksonville 4
Jiaxing 4
Paris 4
Venice 4
Beirut 3
Carrara 3
Dublin 3
Duque de Caxias 3
Fremont 3
Kolkata 3
Massa 3
Porto 3
Rivoli 3
Rochester 3
Seoul 3
Shenyang 3
Totale 4.575
Salva come PNG Salva come JPEG
Nome #
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 178
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 174
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 145
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 143
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 137
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 134
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 132
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 132
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 131
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 129
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 127
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 123
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 121
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 118
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 116
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 116
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 115
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 113
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 109
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation 108
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 105
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 105
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 104
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 104
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 104
Mechanisms underlying the non-anticoagulant effects of apixaban and dabigatran on the integrity of intestinal mucosa: a comparative pre-clinical study. 103
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 102
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? 100
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 98
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 95
Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review 92
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 91
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice 90
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 90
Rifaximin Displays a Protective Activity in Experimental Enteropathy Induced by Indomethacin in Rats. 89
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 88
P2X7 receptor-dependent tuning of gut epithelial responses to infection 87
Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat 86
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 86
Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. 84
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy 83
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 83
Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis 80
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 77
Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling 72
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 71
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases 70
Neuronal regulation of intestinal immune functions in health and disease 69
Adenosine signaling in the tumor microenvironment 69
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 64
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 64
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 62
Donepezil improves vascular function in a mouse model of Alzheimer's disease 62
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence 61
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 59
- Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases 57
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 56
Intestinal epithelial barrier and neuromuscular compartment in health and disease 53
The adenosine system at the crossroads of intestinal inflammation and neoplasia 53
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 52
From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease 52
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation 51
Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy 50
Enteric glia at the crossroads between intestinal immune system and epithelial barrier: Implications for parkinson disease 44
Inflammatory Bowel Diseases: It's Time for the Adenosine System 42
Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches 39
NKG2A and COVID-19: another brick in the wall 38
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications 36
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 35
Editorial: IBD Management—Novel Targets and Therapeutic Perspectives 35
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 33
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 33
The intestinal barrier in disorders of the central nervous system 27
LRRK2 is reduced in Parkinson’s disease gut 26
Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling 25
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis 25
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 21
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 20
Pharmacological modulation of P2X4 in inflammatory bowel diseases: the way towards novel therapeutics? 18
Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson's disease 12
Pathological Remodeling of the Gut Barrier as a Prodromal Event of High-Fat Diet-Induced Obesity 12
Adenosine signaling as target in cardiovascular pharmacology 11
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) 11
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines 9
Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients 9
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 7
Neuromuscular Function Abnormalities 7
Gut-directed therapy in Parkinson’s disease 6
Are LRRK2 mysteries lurking in the gut? 4
Gastrointestinal dysmotility in rodent models of Parkinson’s disease 3
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 2
Totale 6.564
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.829
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.000 0 0 26 95 120 137 121 105 157 89 115 35
2020/2021765 61 61 67 32 43 33 31 53 102 119 39 124
2021/2022759 27 16 18 25 146 113 41 36 62 46 49 180
2022/20231.254 127 159 93 97 121 147 26 111 227 41 84 21
2023/20241.363 80 108 166 100 189 221 54 83 79 50 113 120
2024/2025219 57 117 45 0 0 0 0 0 0 0 0 0
Totale 6.564